This study is a prospective, single-center, phase II clinical trial designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) combined with regorafenib in patients with advanced hepatocellular carcinoma (HCC) who have received at least one prior line of systemic therapy. The trial employs a single-arm design.
Study endpoint
Primary endpoint:
ORR
Secondary endpoint:
DCR, PFS, and OS evaluated based on RECIST v1.1. The incidence and severity of adverse events (AEs)